Navigation Links
Pearl Therapeutics Advances Its Long-Acting Bronchodilator Combination Product Candidate into Four Additional Phase 2 Studies
Date:6/16/2011

earl's chief executive officer. "Pearl has instituted an iterative and integrated clinical and product development process that allows us to conduct clinical studies rapidly while maintaining a high level of rigor. Combining our novel scientific platform with our unique operational construct, we were able to complete an eight-arm, randomized, active- and placebo-controlled Phase 2b study of PT003 in fewer than nine months. We anticipate completing the four new Phase 2 studies in about 12 months, making top-line results available by mid 2012. Following the conclusion of these studies, we will meet with the U.S. Food and Drug Administration to review plans for a registrational Phase 3 program of PT003."

With the exception of the cardiovascular safety study, the primary endpoints of the Phase 2 studies will be improvement in bronchodilation as assessed by change in FEV1* (AUC0-12) relative to baseline. The cardiovascular safety study will measure the change in mean heart rate averaged over 24 hours following chronic administration of PT003, PT005, PT001 or Foradil compared to baseline obtained during the screening period. Heart rate will be evaluated using Holter monitoring. More than 500 patients with moderate-to-severe COPD will be enrolled in these four studies.

"The insights we gained from our first Phase 2b study, and those from the forthcoming Phase 2 studies will provide a strong foundation for selecting the most effective and safe doses of GP and FF in PT003 for Phase 3 trials," added Colin Reisner, chief medical officer and executive vice president of clinical development and medical affairs at Pearl Therapeutics. "We are building additional confidence in our dose selection by comparing GP efficacy with that of a short-acting muscarinic antagonist, Atrovent, in our Phase 2 study of PT001 before progressing into Phase 3. This will strengthen our GP clinical experience beyond our already co
'/>"/>

SOURCE Pearl Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pearl Therapeutics Phase 2b Results Show a 50% Improvement in Lung Function with PT003 Compared to Spiriva® and Foradil® in Patients with COPD
2. Asante Solutions Receives FDA Clearance for Pearl™ Insulin Pump
3. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
4. Pearl Therapeutics to Present Complete PT003 Results from Phase 2b COPD Study in a Late-Breaker Session at the American Thoracic Society Annual Meeting
5. Asante Solutions, Inc. Receives CE Mark for Pearl™ Insulin Pump
6. Sanofi Enters Into Research Collaboration With Biopharmaceutical Company Audion Therapeutics to Develop Potential Treatments for Hearing Loss
7. Cardinal Health, Prime Therapeutics Renew Primary Distribution Agreement
8. Cell Therapeutics Completes Type A Meeting With FDAs Division of Oncology Drug Products: Guidance Provided for Resubmission of Pixantrone NDA for Consideration of Accelerated Approval
9. Novelos Therapeutics to Present at the 5th Lippert/Heilshorn Life Sciences & Medical Technologies Virtual Conference on June 16
10. Grifols Announces Combined Operations With Talecris to Begin a New Era as a Global Leader of Life-Saving Plasma Therapeutics
11. Healthpoint Biotherapeutics to Present at Upcoming Investment Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... , Spanien, September 23, 2014 ... dass sich Fernzugriffe auf eTMF im Jahr ... ermöglicht den Sponsoren von klinischen Versuchsreihen, die ... und Vollständigkeit von Stammdateien mit Informationen über ... zu erfüllen     Die bisher ...
(Date:9/22/2014)... 22, 2014 Levi & Korsinsky is investigating ... "the Company") (NasdaqGS: SIAL ) for possible ... law in connection with the sale of the Company ... to learn more about the investigation: http://zlkdocs.com/SIAL-Info-Request-Form_ma-2199 , ... to you. Under the terms of the ...
(Date:9/22/2014)... , Sept. 22, 2014 Avanir Pharmaceuticals, ... it is offering to sell $200 million of its ... Deutsche Bank Securities and BofA Merrill Lynch are acting ... grant the underwriters a 30-day option to purchase additional ... to be sold in the offering are being sold ...
Breaking Medicine Technology:Branchenweite Umfrage zeigt, dass sich Fernzugriffe auf eTMF im Jahr 2015 verdoppeln werden 2Branchenweite Umfrage zeigt, dass sich Fernzugriffe auf eTMF im Jahr 2015 verdoppeln werden 3Branchenweite Umfrage zeigt, dass sich Fernzugriffe auf eTMF im Jahr 2015 verdoppeln werden 4Branchenweite Umfrage zeigt, dass sich Fernzugriffe auf eTMF im Jahr 2015 verdoppeln werden 5SIGMA-ALDRICH INVESTOR ALERT: Levi & Korsinsky, LLP Investigates the Board of Directors of Sigma-Aldrich Corporation In Connection with the Sale of the Company to Merck -- SIAL 2Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 3
... S.C., Sept. 9 At approximately 3:21,PM ... Chairman and Founder of,CureHIV.us, agreed to act ... Global,Humanceuticals, Inc,s., new extremely effective, safe and ... non-government, U.S.,and foreign institutions, organizations, and corporations, ...
... Effective Antibiotics Against ,Superbugs, BOSTON, Sept. 6 ... may have discovered the path,toward developing better drugs ... resistance to common antibiotics. The,researchers have discovered a ... opens to door to new avenues of research., ...
Cached Medicine Technology:Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug 2Boston University Biomedical Engineers Find Chink in Bacteria's Armor 2Boston University Biomedical Engineers Find Chink in Bacteria's Armor 3
(Date:9/23/2014)... September 23, 2014 Steven Winter Associates, ... firm’s recent projects in the State of Connecticut – ... Gateway at 570 – were honored by the Connecticut ... Awards held on September 18, 2014 at Stepping Stones ... High School, Bridgeport , Recipient of the Institutional Award ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 ... of 3.7 out of 5, indicating moderate buyer ... portable and range from basic household carbon monoxide ... gas concentrations in parts per million. Buyers benefit ... choice of many suppliers, especially amongst distributors,” according ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 Ale Gicqueau, ... presenting on Advanced Data Visualization for Clinical Trials at ... SDE in San Francisco on Friday, September 26, 2014. ... by volunteers. Since its inception, PhUSE has expanded from ... to a global platform for the discussion of topics ...
(Date:9/23/2014)... With the emergence of CVS Health and its ... retail chains are transforming the healthcare landscape to provide ... shoppers. In this capacity, Inside Pharmacy™ is a forum ... share their knowledge on patient care, achieve professional success, ... with other colleagues inside the pharmacy. , This latest ...
(Date:9/23/2014)... September 23, 2014 Published by Nationwide Lifts, ... issues to take charge of their mobility in a new ... positively impactful. Stair lifts are that equipment and ... “Being in the elevator business, I’ve seen so ... themselves or a loved one with mobility issues,” said Andy ...
Breaking Medicine News(10 mins):Health News:Steven Winter Associates’ Projects Receive 2014 Green Building Awards 2Health News:Steven Winter Associates’ Projects Receive 2014 Green Building Awards 3Health News:Gas Detectors Procurement Category Market Research Report Now Available from IBISWorld 2Health News:Gas Detectors Procurement Category Market Research Report Now Available from IBISWorld 3Health News:Clinovo Sponsors and Presents at Pharmaceutical Users Software Exchange (PhUSE) SDE in San Francisco 2Health News:Retail Pharmacies at the Forefront of Primary Care Innovation 2Health News:Nationwide Lifts, America’s Leader in Home Elevators, Is Proud to Announce the Release of Its First Book, “Stair Lifts: Move Up, Not Out!” 2
... when therapy goes to more than just severe cases, ... Pregnant women who receive treatment for the mildest forms ... self-monitoring of blood glucose levels and possibly insulin therapy ... or develop preeclampsia or high blood pressure during pregnancy, ...
... ... Kraft , ... September 30, 2009 -- The Boston biotechnology industry will get an early look at biotech,s ... 27, 2009 at Harvard Medical School. , , ,At the one-day event, recently funded companies ...
... children don,t see their family dentist until they are well ... both dental and medical professionals. , That,s one of the ... conducted on behalf of Delta Dental Plans Association, the nation,s ... gain greater knowledge about the state of children,s oral health. ...
... Incorporated (NYSE: HR ) announced it has entered into ... previous $400 million facility. The new facility includes 16 ... priced at 2.80% over LIBOR, with a 0.40% facility fee, ... loans of this nature. , Healthcare Realty Trust ...
... TOLEDO, Ohio, Sept. 30 Heartland Information Services, a ... Brett S. Himes to President and Chief Executive Officer. ... will assume the President and CEO position immediately. , ... C. Cirino, who has accepted a new position with ...
... Walter and Eliza Hall Institute researchers have put an ... a molecular messenger called Fas ligand is responsible for ... Apoptosis is an important process in human biology ... bodies, protecting us against cancer development and diseases where ...
Cached Medicine News:Health News:Study Urges Treatment for Even Mild Gestational Diabetes 2Health News:Study Urges Treatment for Even Mild Gestational Diabetes 3Health News:Boston Biotech R&D Conference to Showcase Next-Generation Newsmakers and Massachusetts as Leader in Biotech Discovery 2Health News:Boston Biotech R&D Conference to Showcase Next-Generation Newsmakers and Massachusetts as Leader in Biotech Discovery 3Health News:Delayed First Visit to Dentist Can Affect Children's Lifelong Oral Health 2Health News:Healthcare Realty Trust Announces New $550 Million Unsecured Revolving Credit Facility 2Health News:Heartland Information Services Appoints New Chief Executive Officer 2Health News:Research puts a 'Fas' to the cause of programmed cell death 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: